BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

Q3 2023 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Nov 02, 2023 / 12:30PM GMT
Release Date Price: $5.64 (-1.57%)
Operator

Good morning, and welcome to the BioCryst Pharmaceuticals' Third Quarter 2023 Earnings Conference Call. (Operator Instructions). Please note, this event is being recorded.

I would like now to turn the conference over to John Bluth at BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thank you, Maria. Good morning, and welcome to BioCryst's Third Quarter 2023 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer and Chief Data and Insights Officer, Jinky Rosselli. Following our remarks, we'll answer your questions.

As a reminder, tomorrow at 1:00 p.m. Eastern Time, we'll be hosting an R&D Day where we plan to describe our drug discovery process and introduce additional therapies from our pipeline. So today, we'll focus on ORLADEYO, and tomorrow, we'll take a deep dive and answer your question on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot